Sirona, Bloom Burton makes anti-inflammatory compound
Mr. Howard Verrico reports
SIRONA BIOCHEM ANNOUNCES SUCCESSFUL SYNTHESIS OF ANTI-INFLAMMATORY COMPOUND FOR BLOOM BURTON & CO. JOINT VENTURE
Sirona Biochem Corp. has achieved the first batch of compound in the joint venture with Bloom Burton & Co. Compounds developed within the framework of the JV will be entering development in the areas of rare inflammatory and infectious diseases.
At present, there are unmet market needs in the areas of rare or neglected inflammatory diseases and bacterial resistance. Sirona and Bloom Burton are identifying and designing a library of compounds to address these substantial markets which combined reach nearly $2-billion (U.S.) each year globally. Sirona is responsible for the chemistry and Bloom Burton for the financing, clinical validation as well as the commercialization of the compounds.
“We could not be more pleased with the completion of the first synthetic compounds. This is a major milestone in the development of our portfolio for rare and neglected diseases,” said Howard Verrico, chief executive officer of Sirona Biochem. “The team at Bloom Burton will plan for the testing of our new anti-inflammatory compounds in the near future. In the next several months, we will be working on the development of further compounds for our JV with Bloom Burton as planned.”
© 2014 Canjex Publishing Ltd. All rights reserved.
- Published in Life Sciences
Oxford Resources Corporate Update
Vancouver, BC – July 30, 2014: Oxford Resources Inc. (OXI — TSX.V) (“Oxford” or the “Company”) announces that it has settled $30,357.60 in debt owed to a certain creditor of the Company by the issuance of 607,152 common shares at a deemed price of $0.05 per share with a hold period expiring November 25, 2014.
Additionally, the Company has recently converted it’s 20{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} working interest in the Ike Property (formerly the Tasco property) which was recently optioned to Amarc Resources Ltd. to a 1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} NSR for the payment of $50,000.00 received on June 4, 2014.
The Company intends to focus its efforts on a work program proposal from Apex on the Company’s 100{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} owned Aley Creek Niobium property.
About the Aley Creek niobium property
Oxford’s Aley Creek property comprises eight mineral claims in two separate blocks (North and South) totalling over 3,360 hectares within the Omineca mining division, approximately 140 kilometres north of Mackenzie, B.C., Canada.
The Aley carbonatite, which hosts Taseko’s Aley niobium deposit, is associated with a prominent regional airborne magnetic high anomaly within rocks of the Ordovician Kechika formation. Rock and soil samples collected by APEX during 2013 encountered anomalous niobium values in Kechika formation rocks on the Aley Creek North claim block, indicating the potential for rare earth element (REE) bearing lamprophyre and carbonatite occurrences within the property.
Within the Aley Creek South claim block, 6.5 kilometres south of Taseko’s Aley niobium deposit, a distinct two-by-two-kilometre magnetic anomaly occurs. Based on similarities between the Aley Creek South anomaly and the magnetic signature of the Aley niobium deposit there is the potential for the existence of an undiscovered carbonatite intrusion within Oxford’s claims. Currently no carbonatite occurrences are known on the Aley Creek South claim block and no known surface geological work or diamond drilling has occurred within the claims.
APEX is currently in the process of planning a follow-up program including but not limited to, a detailed ground magnetic survey to better define the geometry of the airborne anomaly, as well as follow-up rock and soil sampling, and geological mapping to identify the presence of carbonatite dikes or fenitized host rock suggestive of a proximal carbonatite intrusion. Contingent on the results of the planned phase one exploration, diamond drill testing of the Aley Creek South magnetic anomaly may be warranted.
ON BEHALF OF THE BOARD OF DIRECTORS
OXFORD RESOURCES INC.
Mitchell Adam
President, Director
Tel: 604-343-4546
mitch@mgacapital.net
www.oxfordres.com
- Published in Mining
Argex issues Invitations to Bid to global EPC firms
MONTREAL, July 29, 2014 /CNW Telbec/ – Argex Titanium Inc. (TSX: RGX) (“Argex” or the “Company”) announced today that it has issued Invitations to Bid (ITBs) to three global Engineering-Construction (E/C) firms for the construction of Argex’s first industrial scale 50,000 tonne per annum Titanium Dioxide (TiO2) plant. The pre-qualified E/C firms have each successfully executed Engineering, Procurement and Construction (EPC) projects for chemical and industrial facilities, from front end engineering design stage to successful completion including commissioning of these facilities.
Argex has selected Salaberry-de-Valleyfield, Quebec, for the location of its plant. The plant will be located near the Port of Valleyfield and an existing comprehensive railway infrastructure conveniently linking Argex’s future plant to suppliers and customers in the North American market.
About Argex Titanium Inc.
ARGEX Titanium Inc. is a near-term producer of Titanium Dioxide (TiO2) pigment. With a primary goal of advancing rapidly towards production, Argex has adopted a simple and low-risk strategy for the scale-up of its proprietary process.
Forward-Looking Statements
This news release contains statements that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking information and statements may include, among others, statements regarding future plans, costs, objectives or performance of Argex, or the assumptions underlying any of the foregoing. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur, or if any of them do so, what benefits Argex will derive. Forward-looking statements and information are based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Argex’s control. These risks, uncertainties and assumptions include, but are not limited to, those described under “Risk Factors” in Argex’s Annual Information Form for the fiscal year ended December 31, 2013, which is available on SEDAR at www.sedar.com; they could cause actual events or results to differ materially from those projected in any forward-looking statements. Argex does not intend, nor does Argex undertake any obligation, to update or revise any forward-looking information or statements contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Argex Titanium Inc.
- Published in Mining
SIRONA ARRANGES CONVERTIBLE LOANS
Sirona Biochem Corp. (SBM.V) has entered into convertible loan agreements with arm’s-length parties for the purposes of renewing current outstanding loans in the total amount of $670,000. The original loans were taken out in late 2012 and became due this quarter.
The new loans are secured by promissory notes held by each lender, bear interest at a rate of 12 per cent per annum and are due 18 months from the date of advance of each loan or such other mutually agreed upon date. Interest is payable on a quarterly basis at the end of each calendar quarter. Demand payment of each loan and accrued interest thereon may be made after one year from the date of advance of such loan.
Each lender has the right to elect, at its sole discretion, to convert all or a portion of its loan, including accrued interest, at any time during the term of such loan into common shares of the company at a price of 12 cents per share.
Any shares issued as a result of the conversion of the loans will be subject to applicable regulatory hold periods expiring four months and one day from the date of issue of such shares.
The loan agreements and all securities proposed to be issued thereunder as a result of conversion are subject to the acceptance of the TSX Venture Exchange.
We seek Safe Harbor.
- Published in Life Sciences
Oxford Resources 607,152 shares for debt
<p>The TSX Venture Exchange has accepted for filing the company’s proposal to issue 607,152 shares to settle outstanding debt of $30,357.60.</p>
<p>Number of creditors: One creditor</p>
<p>The company shall issue a news release when the shares are issued and the debt extinguished.</p>
- Published in Mining
Sirona licensee completes two SBM-TFC-039 studies
<p>SIRONA BIOCHEM ANNOUNCES SUCCESSFUL COMPLETION OF TWO FIRST LINE STUDIES BY WANBANG BIOPHARMACEUTICALS</p>
<p>Sirona Biochem Corp. has provided an update. Wanbang Biopharmaceuticals has completed two preclinical efficacy studies of the SGLT2 inhibitor SBM-TFC-039. The studies independently confirm that SBM-TFC-039 increased urinary glucose excretion and improved oral glucose tolerance in normal SD rats. The results were consistent with those previously completed by Sirona Biochem.</p>
<p>The next steps in the validation of SBM-TFC-039 will be the pharmacokinetic study and the 14-day toxicology repeated administration on normal SD rats. If further positive results are obtained, as expected, Wanbang will have completed the first milestone of its licence agreement with Sirona Biochem. This will trigger a second payment to Sirona from Wanbang Biopharmaceuticals, part of the $9.5-million in upfront and milestone payments.</p>
<p>According to a 2013 study published in the Journal of the American Medical Association the People’s Republic of China now has the greatest prevalence of diabetes. It is estimated that 11.6 per cent of the adult population or 114 million people are affected; this is the first time that a country has surpassed the United States, which has an estimated 11.3 per cent living with the disease.</p>
<p>It is also estimated that approximately half of all Chinese adults, a total of 493 million people, could be suffering from prediabetes, a preliminary stage in which the sugar metabolism is already disturbed, but diabetes is not yet present.</p>
<p>”Wanbang Biopharmaceuticals’ dedication to quickly advancing this project to clinical trials confirms the strength of Sirona’s partnership with China’s top-ranked diabetes pharmaceutical company. The value of this pharmaceutical to Sirona grows both within China, home of the world’s largest diabetic population and outside China to other potential pharmaceutical partners,” said Howard Verrico, chief executive officer of Sirona Biochem.</p>
<p>We seek Safe Harbor.</p>
<p><span id=”MainContent_NewsHeader”>2014-07-23 07:51 ET – News Release</span></p>
<p>Mr. Howard Verrico reports</p>
- Published in Life Sciences
Sirona Biochem Corporation – CEO Letter to Shareholders
<p id=”yui_3_16_0_1_1406034781965_1472″><span style=”font-family: arial; font-size: 12pt;”><span id=”yui_3_16_0_1_1406034781965_1471″ class=”mw_region”>VANCOUVER, BC</span>–(Marketwired – July 21, 2014) – Sirona Biochem Corp. <span class=”mw_ticker”>(TSX VENTURE: SBM)</span> <span class=”mw_ticker”>(<a href=”http://finance.yahoo.com/q?s=srbcf” data-rapid_p=”8″>SRBCF</a>)</span> <span class=”mw_ticker”>(<a href=”http://finance.yahoo.com/q?s=zsb.f” data-rapid_p=”9″>ZSB.F</a>)</span> today provided a business update. </span></p>
<p id=”yui_3_16_0_1_1406034781965_1479″><span style=”font-family: arial; font-size: 12pt;”>Dear Shareholders and Investors,</span></p>
<p id=”yui_3_16_0_1_1406034781965_1481″><span style=”font-family: arial; font-size: 12pt;”><img style=”float: right;” src=”http://www.financialbuzz.com/videos/07212014/howard.jpg” alt=”Howards” width=”203″ height=”286″ />As announced in our recent news release, I, Howard Verrico, have stepped in as CEO of Sirona Biochem. Although this change is significant, I have always maintained an active role in Sirona’s operations throughout its history making this an efficient transition. I can assure you we are moving along on all initiatives as planned. As founder, Chairman of the Board and a major shareholder I will personally ensure the re</span><span style=”font-family: arial; font-size: 12pt;”>sponsibilities and deliverables of CEO are achieved. Under supervision of Sirona’s Board, the search, selection and appointment of a new executive management team member will occur as a priority task.</span></p>
<p><span style=”font-family: arial; font-size: 12pt;”><strong>Financial: </strong></span></p>
<p><span style=”font-family: arial; font-size: 12pt;”>In February 2014, we announced the completion of a $1.2M private placement. The original plan was to follow this up with a US led investment of approximately $4 million. This initiative was abandoned since terms did not meet our vision for the direction of our company. The management of the company was and is unwilling to settle for terms that we feel create risk to the current shareholder value. </span></p>
<p id=”yui_3_16_0_1_1406034781965_1484″><span style=”font-family: arial; font-size: 12pt;”>We anticipate minimal financing needs over the next twelve to eighteen months. To avoid unnecessary dilution, we will continue to apply for government grants and loans where applicable rather than pursue an equity raise. Moreover, we are expecting further substantial milestone payments as well as initial royalty payments.</span></p>
<p id=”yui_3_16_0_1_1406034781965_1538″><span style=”font-family: arial; font-size: 12pt;”>Our current institutional investors remain very supportive of our future growth strategy. We have recently been encouraged by strong interest from European investors which could bode very well for us going forward. In addition to that, we plan to further increase market awareness for Sirona in the next several months.</span></p>
<p id=”yui_3_16_0_1_1406034781965_1540″><span style=”font-family: arial; font-size: 12pt;”><strong>Strategy: </strong></span></p>
<p id=”yui_3_16_0_1_1406034781965_1542″><span style=”font-family: arial; font-size: 12pt;”>Sirona Biochem remains committed to a streamlined business strategy of chemistry, patent and license. </span></p>
<p id=”yui_3_16_0_1_1406034781965_1544″><span style=”font-family: arial; font-size: 12pt;”>Our expertise remains in creating new chemical compounds (pharmaceutical and cosmetic) that have distin</span><span style=”font-family: arial; font-size: 12pt;”>ct advantages over existing technologies. Each compound that we create will be licensed to an industry-leading company who will be responsible for developing, manufacturing and selling the compound. In return, Sirona will receive licensing fees, milestone payments and ongoing royalty payments. </span></p>
<p><span style=”font-family: arial; font-size: 12pt;”><span id=”yui_3_16_0_1_1406034781965_1471″ class=”mw_region”><img style=”float: left;” src=”http://www.financialbuzz.com/videos/07212014/siron.jpg” alt=”Lab” width=”297″ height=”197″ /></span></span><span style=”font-family: arial; font-size: 12pt;”>Through our platform technology, we have been able to diversify our risk across multiple projects, increase our portfolio size more quickly and continue to build our credibility and reputation as experts in the discovery of innovative therapeutics.</span></p>
<p><span style=”font-family: arial; font-size: 12pt;”>The Board of Directors is taking an increasingly active role in refining the company strategy and how it is implemented. Our Board has a diverse and valuable skill set which we are utilizing to the fullest extent. </span></p>
<p><span style=”font-family: arial; font-size: 12pt;”><strong>Operations: </strong></span></p>
<p><span style=”font-family: arial; font-size: 12pt;”>In March, we bolstered our France team with the addition of Claude Nivet. Claude’s official title is Laboratory Manager. This role was developed specifically to assist in growing operations and relieving our Chief Scientific Officer, Geraldine Deliencourt-Godefroy, of some of her non-scientific tasks. This will allow her to focus on innovation and management of the current pipeline. </span></p>
<p><span style=”font-family: arial; font-size: 12pt;”>Our current R&D focus is on the following: </span></p>
<ul id=”yui_3_16_0_1_1406034781965_1602″ style=”list-style-type: disc;”>
<li><span style=”font-family: arial; font-size: 12pt;”>Assist Obagi/Valeant in the manufacturing and monetization of our skin lightener. Obagi/Valeant will be responsible for the formulation and sales of the compound;</span></li>
<li id=”yui_3_16_0_1_1406034781965_1601″><span style=”font-size: 12pt;”>Develop the anti-aging library of compounds in anticipation of government funding and commencement of pre-clinical studies; </span></li>
<li><span style=”font-size: 12pt;”>Synthesize the anti-inflammatory compound for our Bloom Burton partnership.</span></li>
</ul>
<p id=”yui_3_16_0_1_1406034781965_1604″><span style=”font-family: arial; font-size: 12pt;”><br />As projects progress and resources become available, we will explore new areas where our technology will add significant value.</span></p>
<p><span style=”font-family: arial; font-size: 12pt;”><strong>Current Business Development: </strong></span></p>
<ul id=”yui_3_16_0_1_1406034781965_1607″ style=”list-style-type: disc;”>
<li><span style=”font-family: arial; font-size: 12pt;”>At the end of April 2014, Wanbang Biopharmaceuticals began pre-clinical validation for Sirona Biochem’s second generation SGLT2 Inhibitor. To date, Sirona has received Wanbang’s initial licensing fee and the Chinese government’s innovation tax application has been approved. Wanbang has successfully hired an expert in pharmacology and toxicity to lead the project and compound synthesis has begun to ensure quantities of the compound will be available for all future clinical trials. Further updates from Wanbang will become available shortly.</span></li>
<li id=”yui_3_16_0_1_1406034781965_1606″><span style=”font-size: 12pt;”>Obagi Medical Products is moving forward on Sirona Biochem’s skin lightening compound TFC-849. Obagi Medical Products is responsible for all development, manufacturing and sales of the compound and in return Sirona Biochem will receive licensing and milestone fees and ongoing royalty payments.</span></li>
<li><span style=”font-size: 12pt; font-family: arial;”>Our Joint Venture with Bloom Burton and Co. is progressing nicely. Once the first compound is synthesized, it will enter early stage testing. Bloom Burton is Canada’s largest and most active healthcare-specialized investment banking firm. The goal of this joint venture is to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.</span></li>
<li><span style=”font-size: 12pt;”>Sirona’s Chief Scientific Officer recently attended industry meetings in New York City. The meetings were very successful and have generated multiple potential partnerships. We will provide updates regarding these opportunities on the next shareholder letter. Although we have a number of significant partnering initiatives fully executed and underway, we are continuing to explore new partnership opportunities and currently have multiple ongoing conversations with large Pharma and cosmetic companies around the world.</span></li>
</ul>
<p><span style=”font-family: arial; font-size: 12pt;”><br />Our goal has always been for Sirona Biochem to become the global leader in the process of compound stabilization which leads to unlimited applications in pharmaceuticals and cosmetics. The value of Sirona Biochem lies in its technology and we intend to put our resources behind this. At the end of the day, our common goal is to create shareholder value which is exactly what we work to accomplish every single day. Sirona is well positioned to take advantage of some of the major opportunities that are available to us and we are working diligently to take our company to the next level. </span></p>
<p><span style=”font-family: arial; font-size: 12pt;”>I sincerely appreciate the past support of our shareholders and ask for your future support as we move forward. </span></p>
<p><span style=”font-family: arial; font-size: 12pt;”>Best Regards,</span></p>
<p><span style=”font-family: arial; font-size: 12pt;”>Dr. Howard Verrico</span><br /><span style=”font-family: arial; font-size: 12pt;”> CEO, Chairman of the Board</span><br /><span style=”font-family: arial; font-size: 12pt;”> Sirona Biochem </span></p>
<p><span style=”font-family: arial; font-size: 12pt;”><strong>About Sirona Biochem Corp. </strong></span></p>
<p id=”yui_3_16_0_1_1406034781965_1609″><span style=”font-family: arial; font-size: 12pt;”>Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information please visit <a href=”http://www.sironabiochem.com/” rel=”nofollow” data-rapid_p=”10″>www.sironabiochem.com</a>.</span></p>
<p>Contact:</p>
<p><span style=”font-family: arial; font-size: 12pt;”> For more information regarding this press release, contact:</span><br /><span style=”font-family: arial; font-size: 12pt;”>Christopher Hopton </span><br /><span style=”font-family: arial; font-size: 12pt;”>CFO</span><br /><span style=”font-family: arial; font-size: 12pt;”>Sirona Biochem Corp. </span><br /><span style=”font-family: arial; font-size: 12pt;”>Phone: 1.604.282.6064</span><br /><span style=”font-family: arial; font-size: 12pt;”>Email: <a href=”mailto:chopton@sironabiochem.com” rel=”nofollow” data-rapid_p=”11″>chopton@sironabiochem.com</a></span></p>
- Published in Life Sciences
SIRONA BIOCHEM CORPORATION – CEO LETTER TO SHAREHOLDERS
Sirona Biochem Corp. has provided a business update in the form of a shareholders letter from the chief executive officer.
Dear shareholders and investors,
As announced in our recent news release, I, Howard Verrico, have stepped in as chief executive officer of Sirona Biochem. Although this change is significant, I have always maintained an active role in Sirona’s operations throughout its history, making this an efficient transition. I can assure you we are moving along on all initiatives as planned. As founder, chairman of the board and a major shareholder, I will personally ensure the responsibilities and deliverables of chief executive officer are achieved. Under supervision of Sirona’s board, the search, selection and appointment of a new executive management team member will occur as a priority task.
Financial
In February, 2014, we announced the completion of a $1.2-million private placement. The original plan was to follow this up with a U.S.-led investment of approximately $4-million. This initiative was abandoned since terms did not meet our vision for the direction of our company. The management of the company was and is unwilling to settle for terms that we feel create risk to the current shareholder value. We anticipate minimal financing needs over the next 12 to 18 months. To avoid unnecessary dilution, we will continue to apply for government grants and loans, where applicable, rather than pursue an equity raise. Moreover, we are expecting further substantial milestone payments, as well as initial royalty payments.
Our current institutional investors remain very supportive of our future growth strategy. We have recently been encouraged by strong interest from European investors, which could bode very well for us going forward. In addition to that, we plan to further increase market awareness for Sirona in the next several months.
Strategy
Sirona Biochem remains committed to a streamlined business strategy of chemistry, patent and licence.
Our expertise remains in creating new chemical compounds (pharmaceutical and cosmetic) that have distinct advantages over existing technologies. Each compound that we create will be licensed to an industry-leading company who will be responsible for developing, manufacturing and selling the compound. In return, Sirona will receive licensing fees, milestone payments and ongoing royalty payments.
Through our platform technology, we have been able to diversify our risk across multiple projects, increase our portfolio size more quickly, and continue to build our credibility and reputation as experts in the discovery of innovative therapeutics.
The board of directors is taking an increasingly active role in refining the company strategy and how it is implemented. Our board has a diverse and valuable skill set, which we are utilizing to the fullest extent.
Operations
In March, we bolstered our France team with the addition of Claude Nivet. Claude’s official title is laboratory manager. This role was developed specifically to assist in growing operations and relieving our chief scientific officer, Geraldine Deliencourt-Godefroy, of some of her non-scientific tasks. This will allow her to focus on innovation and management of the current pipeline. Our current research and development focus is on the following:
- Assist Obagi/Valeant in the manufacturing and monetization of our skin lightener; Obagi/Valeant will be responsible for the formulation and sales of the compound;
- Develop the anti-aging library of compounds in anticipation of government funding and commencement of preclinical studies;
- Synthesize the anti-inflammatory compound for our Bloom Burton partnership.
As projects progress and resources become available, we will explore new areas where our technology will add significant value.
Current business development
- At the end of April, 2014, Wanbang Biopharmaceuticals began preclinical validation for Sirona Biochem’s second-generation SGLT2 Inhibitor. To date, Sirona has received Wanbang’s initial licensing fee, and the Chinese government’s innovation tax application has been approved. Wanbang has successfully hired an expert in pharmacology and toxicity to lead the project, and compound synthesis has begun to ensure quantities of the compound will be available for all future clinical trials. Further updates from Wanbang will become available shortly.
- Obagi Medical Products is moving forward on Sirona Biochem’s skin lightening compound TFC-849. Obagi Medical Products is responsible for all development, manufacturing and sales of the compound, and, in return, Sirona Biochem will receive licensing and milestone fees and ongoing royalty payments.
- Our joint venture with Bloom Burton and Co. is progressing nicely. Once the first compound is synthesized, it will enter early stage testing. Bloom Burton is Canada’s largest and most active health-care-specialized investment banking firm. The goal of this joint venture is to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.
- Sirona’s chief scientific officer recently attended industry meetings in New York City. The meetings were very successful and have generated multiple potential partnerships. We will provide updates regarding these opportunities on the next shareholder letter. Although we have a number of significant partnering initiatives fully executed and under way, we are continuing to explore new partnership opportunities and currently have multiple ongoing conversations with large pharma and cosmetic companies around the world.
Our goal has always been for Sirona Biochem to become the global leader in the process of compound stabilization, which leads to unlimited applications in pharmaceuticals and cosmetics. The value of Sirona Biochem lies in its technology, and we intend to put our resources behind this. At the end of the day, our common goal is to create shareholder value, which is exactly what we work to accomplish every single day. Sirona is well positioned to take advantage of some of the major opportunities that are available to us, and we are working diligently to take our company to the next level.
I sincerely appreciate the past support of our shareholders and ask for your future support as we move forward.
Best regards,
Dr. Howard Verrico
Chief executive officer, chairman of the board
Sirona Biochem
- Published in Life Sciences
Sirona hires PRC Partners for consulting services
<p>SIRONA ANNOUNCES SHARES FOR SERVICES AGREEMENT</p>
<p>Sirona Biochem Corp. has entered into a business consulting agreement with PRC Partners Ltd. of Hong Kong for a six-month term commencing July 15, 2014. As compensation for the services to be provided, PRC will receive a total of 1,500,000 common shares of the Company, in tranches of 250,000 common shares each, on a monthly basis starting August 15, 2014. PRC will also receive stock options in the Company, under the Company’s stock option plan, entitling it to purchase 500,000 common shares at a price of $0.15 per share and 500,000 common shares at a price of $0.20 per share expiring 60 days after the Agreement is terminated. Services to be provided by PRC include consultation, advice, and the arrangement of strategic relationships with other companies and the acquisition of projects, access to capital markets in Europe, and similar activities designed to further the business and development of the Company.</p>
<p>The Agreement and all securities proposed to be issued thereunder are subject to the acceptance of the TSX Venture Exchange.</p>
<p>About PRC Partners</p>
<p>PRC Partners is a Hong Kong-based corporate development consulting firm owned Frank Haentjes. Mr. Haentjes is a native of Cologne, Germany, raised and educated in Brazil, Germany and the United States. He has been living and working in China for much of the last decade, successfully assisting Canadian public companies in tapping investment funds from State-owned Enterprises and high-net-worth individuals. PRC Partners has a self-professed focus on the discovery of undervalued and promising growth companies, and serves these companies by increasing visibility and accessing capital through an experienced network of investors. Due to the increasing demand from his investors, Mr. Haentjes has taken a strong interest in technology as well as in biotech/healthcare deals that are either public or about to go public. He has extensive relationships in Asia, Europe and the Middle East. He will be providing the services on behalf of PRC Partners.</p>
<p>We seek Safe Harbor.</p>
- Published in Life Sciences
Lakeland Resources Inc. Acquires Newnham Lake Property, Athabasca Basin
Canada NewsWire
VANCOUVER, July 21, 2014
TSXv: LK FSE: 6LL
VANCOUVER, July 21, 2014 /CNW/ – Lakeland Resources Inc. (TSXv: LK) (FSE: 6LL) (OTCQX: LRESG) (the “Company” or “Lakeland”) is pleased to announce that it has acquired the Newnham Lake Property (the “Property”), within the northeast portion of the Athabasca Basin. Newnham Lake is contiguous to the south of the Company’s Karen Lake Property, and increases the company’s land position in the area by approximately 20,218 ha (49,961 acres). The property is situated along the shallow basement margin where depth to basement is expected to be from zero to around 100 metres.
The Newnham Lake Property and surrounding area was the subject of intense exploration efforts by Saskatchewan Mining and Development Corporation (“SMDC”) for shallow, unconformity hosted uranium deposits from about 1976 to 1984. JNR Resources conducted exploration on and near the Property between 1997 and 2011. The recent work includes a ground electromagnetic (HLEM) survey with targets on the Property not yet drill tested. Other recent work includes airborne VTEM and ZTEM surveys and an airborne full tensor gravity gradiometry survey.
The Property encompasses parts of an approximately 25 km long, folded and faulted, graphitic metapelite trend which was the subject of the historic work. In excess of 140 drill holes targeted this trend prior to 1984, and were focused on mineralization at the unconformity. Limited work was done exploring for deeper basement style mineralization despite extensive alteration, anomalous geochemistry and favorable rock types, with most holes continuing less than 25 metres past the sub-Athabasca unconformity. The exploration in the area of the Newnham Lake Property was largely prior to the understanding of the importance of basement-hosted unconformity-style uranium deposits. The Newnham Lake region was one of the most developed trends in the Athabasca Basin, outside of the prolific Eastern Athabasca Trend and Cluff Lake. The company believes that the historic work indicates a large amount of positive exploration indications and that there are several targets yet to be tested.
To the northeast of the Property, within Lakeland’s Karen Lake Property, historic work shows extensive enrichment within lakes and stream sediments of Uranium, Nickel and other pathfinder elements. Organic-rich overburden samples at Karen Lake are reported to contain in excess of 1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} uranium.
According to Jon Armes, President and CEO of Lakeland Resources “We are excited about the opportunity to acquire another project such as Newnham Lake with significant historic work that suggests the presence of a large mineralized system, as evidenced by highly anomalous uranium, nickel and other pathfinders in both drill holes and surface samples. We look at this as an excellent opportunity to grow the Company’s stable of high-quality projects.”
Concurrent with the acquisition of the Newnham Lake Property, the company has also agreed to acquire the Hatchet Lake Property (the “Hatchet Property”). It is located east of the Company’s recently acquired Fond du Lac Property, and covers the easterly extension of what is interpreted as the same basement graphitic meta-sedimentary basin. The Hatchet Property has not seen any serious historic exploration campaigns despite its favourable geological setting. The Hatchet Property is located approximately 12 kilometres outside of the Athabasca Basin sandstones, and is considered highly prospective for basement hosted mineralization. It also benefits from nearby infrastructure, as is common to all projects located within the northeastern part of the Athabasca Basin, and which are in reasonable proximity to the Uranium Mining and Milling infrastructure.
Lakeland has the right to earn a 100{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} interest in the Newnham Lake Property by making cash payments totaling $100,000 and issuing 2,500,000 common shares over a 24 month period. The Vendor will retain a 2.5{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} GORR, subject to a 1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} buyback provision. The Hatchet Lake Property can be acquired by making a cash payment of $13,500 and issuing 500,000 shares. The Vendors will retain a 2.5{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} GORR, subject to a 1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} buyback provision.
NI 43-101 Disclosure
The technical information above has been prepared in accordance with the Canadian regulatory requirements set out in National Instrument 43-101 and reviewed on behalf of the company by Neil McCallum, P.Geo., of Dahrouge Geological Consulting Ltd., a qualified person.
About Lakeland Resources Inc.
Lakeland Resources Inc. is a pure play uranium exploration company focused on the Athabasca Basin in Saskatchewan, Canada; home to some of the world’s largest and richest high-grade uranium deposits. The Company’s common shares trade on the TSX Venture Exchange under the symbol “LK” and on the Frankfurt Stock Exchange under the symbol “6LL”.
On Behalf of the Board of Directors
LAKELAND RESOURCES INC.
“Jonathan Armes”
Jonathan Armes
President, CEO and Director
Cell: 416.708.0243
Ph: 604.681.1568
TF: 1.877.377.6222
Email: jarmes@lakelandresources.com
Web: http://www.lakelandresources.com
Read more: http://www.digitaljournal.com/pr/2066544#ixzz38CrHk7lf
- Published in Mining